Stockscreener 앱 받기
1.04
5.61%
0.06
전일 마감가:
$0.98
열려 있는:
$1.09
하루 거래량:
101.43K
Relative Volume:
0.29
시가총액:
$10.79M
수익:
$1.85M
순이익/손실:
$-5.26M
주가수익비율:
-1.1003
EPS:
-0.9452
순현금흐름:
-
1주 성능:
-22.77%
1개월 성능:
-36.89%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.02
$1.09
1주일 범위
$0.90
$1.36
52주 변동 폭
$0.90
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
명칭
20 20 Biolabs Inc
전화
(240) 453-6339
주소
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
1.03 | 10.27M | 1.85M | -5.26M | 0 | -0.9452 |
ABT
Abbott Laboratories
|
86.14 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
311.87 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.92 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.56 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.81 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc 주식(AIDX)의 최신 뉴스
No Analysis Provided - StocksToTrade
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
AIDX Slides As 20/20 Biolabs Inc. Faces Heavy Selling - timothysykes.com
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand - Sahm
20/20 Biolabs: Buy Rating Reiterated on Growth Outlook and OneTest Momentum; $5 Price Target Maintained - TipRanks
AIDX - Finviz
AIDX Stock Slides As 20/20 Biolabs Tests Key Support - timothysykes.com
20/20 Biolabs stock surges on Ebola testing plans - Investing.com India
20/20 Biolabs stock surges on Ebola testing plans By Investing.com - Investing.com Nigeria
20/20 Biolabs Engages Pcr Test Kit Developers For Ebola And Hantavirus Testing - TradingView
Lab that ran 400,000 COVID tests now preparing for Ebola, hantavirus - Stock Titan
20/20 Biolabs 2Q Loss/Shr 28c >AIDX - Moomoo
20/20 Biolabs (NASDAQ: AIDX) registers 10.105M shares; posts Q1 2026 results - Stock Titan
20/20 Biolabs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
20/20 Biolabs (AIDX) posts lower Q1 revenue and deeper loss after $5M preferred raise - Stock Titan
20/20 BioLabs reports Q1 2026 revenue $0.4M, net loss $2.17M, cash $4.2M - TradingView
Q1 2026: 20/20 BioLabs (AIDX) revenue declines as cash rises on $5M raise - Stock Titan
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - The Manila Times
Press Release: 20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - Moomoo
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout
Maxim Group Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
20/20 Biolabs (AIDX) delays 10-Q filing; expects 5-day extension - Stock Titan
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Number of shareholders of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 - ChartMill
20/20 Biolabs, Inc.Common Stock (NQ: AIDX - FinancialContent
AIDX | 20/20 Biolabs, Inc. Common FinancialsIncome Statement - Quiver Quantitative
USC inks licensing agreement for prostate cancer screening tool - University of South Carolina
20/20 BioLabs Licenses Patented Algorithm from University of South Carolina for Early Detection of Aggressive Prostate Tumors - Quiver Quantitative
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina - The Manila Times
New PSA algorithm uses repeat blood tests to flag high-risk prostate tumors early - Stock Titan
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
AIDX: 20/20 Biolabs Inc.Brokerage Recommendations Chart - Zacks Investment Research
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
A. G. P. Initiates 20/20 BIOLABS INC(AIDX.US) With Buy Rating, Announces Target Price $1.46 - Moomoo
20/20 Biolabs Unchanged on News - Baystreet.ca
How 20/20 Biolabs (AIDX) integrates its acquisitions | AIDX Latest Quarter Earnings: 20/20 Biolabs withholds core EPS and revenue performance metricsViral Momentum Stocks - newser.com
AIDX Latest Quarter Earnings: 20/20 Biolabs withholds core EPS and revenue performance metricsUnderperform - newser.com
20/20 Biolabs Inc. (AIDX) Gross Margin (TTM) - Zacks Investment Research
Is 20/20 Biolabs (AIDX) stock a strong buy |Bond Issuance - newser.com
20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 BioLabs blood test platform targeting early detection of hard-to-screen Cancers - Proactive financial news
20/20 Biolabs (NASDAQ: AIDX) cuts warrant price, registers 15.16M shares - Stock Titan
Warrant strike cut to $2.25 as 20/20 Biolabs (NASDAQ: AIDX) registers 10.1M shares - Stock Titan
Streeterville warrant repricing at 20/20 Biolabs (NASDAQ: AIDX) drops strike - Stock Titan
AIDX (20/20 Biolabs) highlights rising clinical test adoption as core growth driver in latest quarterly earnings.Community Trade Ideas - Newser
How to Value 20/20 Biolabs (AIDX) Stock (Technical Strength) 2026-04-22Community Driven Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La
20/20 BIOLABS INC Company Profile & Introduction - Moomoo
AIDX | 20/20 Biolabs, Inc. Common Insider Trading - Quiver Quantitative
20/20 Biolabs (AIDX) Stock Chart and Price History 2026 - MarketBeat
20 20 Biolabs Inc (AIDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.32%
0.17%
자본화:
|
볼륨(24시간):